ArticleIranian journal of medical sciences2025

Cost-Effectiveness Analysis of Crizanlizumab in Sickle Cell Disease in Iran.

Marzieh Nosrati et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.